Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

R&D operations in California registered with DEA to enable production of new class of cannabinoid pharmaceuticals LOS ANGELES, CA – ( November 1, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

Proprietary cannabinoid drug formulations have now been shown to effectively treat preclinical models of Crohn’s disease and ulcerative colitis LOS ANGELES, CA – (Oct 19, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions LOS ANGELES, CA – (October 16, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological...

Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough

R&D team achieves more than 15-fold improvement in biocatalyst production efficiency LOS ANGELES, CA – (October 4, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory...

Vitality Biopharma Receives Updated SeeThruEquity Price Target of $2.40

LOS ANGELES, CA–(Sep 27, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality”, “Vitality Biopharma”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that SeeThruEquity, a leading independent equity research and corporate access firm...

Vitality Biopharma to Present at The MoneyShow San Francisco Conference

LOS ANGELES, CA–(Aug 23, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality”, “Vitality Biopharma”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to provide a presentation and participate in a cannabis industry panel session at...

Vitality Biopharma Closes $1 Million Private Placement

LOS ANGELES, CA–(Aug 2, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality”, “Vitality Biopharma”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1...

Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

Vitality’s proprietary gut-targeted cannabosides provided marked improvement in challenging colitis efficacy model LOS ANGELES, CA – (July 19, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders,...

Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

Dr. Natasha Ryz, a Vitality research advisor, will present a case study report on cannabinoid treatment for pediatric Crohn’s disease LOS ANGELES, CA – (June 21, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of...

Vitality Biopharma to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA–(May 30, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 7th Annual LD...